UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO
SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
AlerisLife Inc.
(Name of Subject Company)
AlerisLife Inc.
(Name of Person(s) Filing Statement)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
33832D205
(CUSIP Number of Common Stock)
Jeffrey C. Leer
President and Chief Executive Officer
Two Newton Place
255 Washington Street
Suite 230
Newton, Massachusetts 02458
(617) 796-8387
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Person(s) Filing Statement)
With copies to:
Zachary Blume
Suni Sreepada
Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, Massachusetts 02199
(617) 951-7000
x | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Schedule 14D-9C consists of the following documents related to the proposed acquisition of AlerisLife Inc. (the “Company”) pursuant to the terms of that certain Agreement and Plan of Merger among the Company, ABP Acquisition LLC (“Parent”), a Maryland limited liability corporation, and Parent’s wholly owned subsidiary, ABP Acquisition 2 LLC, a Maryland limited liability company.
1) | ||
2) | Letter from Jeffrey C. Leer, the President and Chief Executive Officer of the Company, to the Company’s Employees, dated February 3, 2023. |
The items listed above were first used or made available on February 3, 2023. In addition, the information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by the Company on February 3, 2023 (including all exhibits attached thereto) are incorporated herein by reference.